The Prognostic Value of Chromosome 7 Polysomy in Non-small Cell Lung Cancer Patients Treated with Gefitinib

摘要: Introduction Specific subpopulations of non-small cell lung cancer (NSCLC) patients defined by clinical features and molecular profiles seem to derive greater benefit from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, but no general consensus on testing optimize treatment has emerged. The objective this study was evaluate chromosome 7 polysomy other potential indicators gefitinib efficacy in advanced NSCLC patients. Methods Paraffin-embedded tumors 82 treated with were analyzed immunohistochemistry for expression EGFR markers, fluorescence situ hybridization gene or copy number. Mutational status assessed single-strand conformational polymorphism, sequence-specific polymerase chain reaction, direct sequencing. Molecular characteristics evaluated relation response (OR), progression-free survival (PFS), overall (OS). Results mutational (p = 0.002), never smoking 0.052), 0.029) significant OR. mutation, pAKT PTEN expression, associated longer OS. There a difference OS between the groups 0.015) both pAkt+ 0.002) chromosome7 PTEN+ 0.04). In stepwise proportional hazards analysis, significantly 0.004 0.017 respectively). Conclusion These results suggest that further inhibitors is warranted developing test selecting therapy.